WILMINGTON, Del., Sept. 12, 2025 (GLOBE NEWSWIRE) — ProText Mobility, Inc. (OTC: TXTM), is delighted to announce that the OTC Markets Group (OTCM) informed the company that the “caveat emptor” designation has been removed and the company is current in its corporate filing information, gaining the OTCID Basic Market status. A copy of the Attorney’s letter can be found here.The Latest Quarter Report for the period ending June 30, 2025, can be found here. About Protext (OTC: TXTM)Through its prior acquisitions, Protext has engaged in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology. Website: www.protxtm.com CONTACT INFORMATIONDylon Du Plooy at: dylon@rsammd.co.zaDr.J...

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced that it has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.70 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share that will be exercisable upon issuance and will expire twenty-four months from the effective date of the registration...

Appoints Veteran Luxury and Spirits Marketer Tina Reejsinghani as CMO to Lead Next Phase of Brand Growth NORWALK, Conn., Sept. 12, 2025 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced a series of organizational and leadership updates aimed to enhance its operational efficiency and position the Company for long-term success. Following a careful evaluation of its organizational structure and long-term priorities, Reed’s has concluded that a corporate reorganization was necessary. This step, while not taken lightly, is part of a broader strategic realignment designed to strengthen the Company’s foundation for future growth. In tandem with this effort, Reed’s is advancing key investments to bolster its commercial...

Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company’s Board of DirectorsSOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will...

JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). According to the Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company’s ordinary shares has been $1.00 per share or greater for 10 consecutive business days, from August 27, 2025 to September 10, 2025, and...

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) — NASDAQ-listed Blue Hat Interactive Entertainment Technology Inc. (BHAT) announced that it completed over 123KG (US$13,326,754) in gold trading during the first half of 2025, and projects that trading volume may potentially reach 550KG during fiscal year 2025, subject to market conditions. “This represents progress in the company’s strategic transformation toward gold-focused commodity trading,” stated Mr. Chen Xiaodong, CEO of the company. He further noted: “Mainland China represents one of the world’s largest gold consumption markets. China and India’s gold consumption demand reportedly accounts for over 50% of the global market. Gold is a distinctive commodity with both commercial and monetary attributes. Beyond generating profits through trading,...